Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium adolescentis BD1
- Development stage
- Preclinical
- Lead developer
- Rush University
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium adolescentis BD1 is a specific strain of probiotic bacteria investigated for its potential to improve gut health. It was isolated from a human subject whose gut microbiome had been enriched with the prebiotic galactooligosaccharide (GOS). In a clinical study at Rush University, the BD1 strain was evaluated, both by itself and in a synbiotic combination with GOS, for its ability to modulate the gut microbiota, improve intestinal barrier function, and reduce endotoxemia and metabolic inflammation, particularly in obese adults.
Beyond the preview
Go deeper on Bifidobacterium adolescentis BD1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium adolescentis BD1.